Faculty Presentations




Paul D. Olivo, MD, PhD |
Fig. 01 -
Title Slide
Fig. 02 -
Disclosures
Fig. 03 -
ATD
Fig. 04 -
Autoantibodies
Fig. 05 -
Human
Fig. 06 -
GPCR
Fig. 07 -
Binding
Fig. 08 -
Transduction
Fig. 09 -
3 Types
Fig. 10 -
Stimulating
Fig. 11 -
Blocking
Fig. 12 -
TSHR AA
Fig. 13 -
Commercial
Fig. 14 -
Multiple Generations
Fig. 15 -
Schematic
Fig. 16 -
Bioassays
Fig. 17 -
Examples
Fig. 18 -
Anti-TSHR Nomenclature
Fig. 19 -
Stimulating and Blocking
Fig. 20 -
Clinical Utility
Fig. 21 -
TNH
Fig. 22 -
TBAb in GD & HT
Fig. 23 -
Prevalence
Fig. 24 -
Prevalence (cont)
Fig. 25 -
Patients at Risk
Fig. 26 -
Area of investigation
Fig. 27 -
Thank You!
TODO, let Pete know of any updates to this content
Six (6) provocative statements concerning clinical treatment of IBD. Each statement is presented as 5 steps:Step 1: the statement & introduction, + 5 possible opinions of that statement -- please choose one
Step 2: a graph of an international survey’s opinions of that statement
Step 3: a literature review for that statement
Step 4: a graph comparing the faculty's vs an international survey’s opinions, + faculty discussion
Step 5: a brief faculty summary, plus the list of references.
Please click on any Statement or any Step tab to read this publication in the order you prefer.